Devyser BRCA PALB2 NGS is a fast and robust NGS solution designed for the detection of genetic variants in the BRCA1, BRCA2, and PALB2 genes. It offers comprehensive and uniform coverage of all coding exons and exon/intron junctions of both genes. In addition, it includes the detection of single nucleotide variants (SNVs), insertions/deletions (Indels), and copy number variations (CNVs), in both germline and somatic contexts.

Key Features

Comprehensive variant detection: Identifies relevant genetic variants in the BRCA1, BRCA2, and PALB2 genes, including CNVs.
Fast workflow: optimized for rapid results with same-day library preparation and less than 45 minutes of hands-on time.
A single workflow is easily and effectively applied to two applications: germline and somatic analysis.
Dedicated software: Provides automated, user-friendly analysis, with options for batch export and efficient variant analysis without the need for bioinformatics expertise.
Devyser BRCA PALB2 NGS Workflow

Intended Audience / User

Ideal for laboratories that need to comprehensively analyze the BRCA1, BRCA2, and PALB2 genes in a streamlined workflow. The targeted sequencing approach and uniform coverage of target regions maximize the retrieval of relevant data in every sequencing run.

Benefits

Streamlined workflow: easy to implement and suitable for laboratories with varying sample volume needs. Ready-to-use reagents, ensuring a reproducible process and reducing the risk of sample mix-ups or contamination. Compatible with germline and somatic analysis under the same workflow. Intuitive software: facilitates the interpretation of obtained data, reducing the need for bioinformatics intervention.

Additional Considerations

Starting material: Human genomic DNA extracted from whole blood or FFPE tissue. In FFPE samples, it is necessary to previously evaluate concentration and integrity, as initial sample quality can compromise the assay results.

Ordering Information

Devyser BRCA PALB2 Kits
8-A408-8 8 tests
8-A408-24 24 tests
8-A408-96 96 tests
Purification, Sequencing, and Analysis
Purification Devyser Library Clean (8-A204) for library purification.
Sequencing Sequencing on Illumina MiSeq.
Analysis Analysis in Amplicon Suite with Devyser BRCA PALB2 pipeline.

Area:

Hereditary cancer, Molecular Genetics, Solid tumor, Targeted study of specific pathologies

Brand:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

Franklin by QIAGEN for Somatic Analysis

Advanced cloud-based bioinformatics platform designed for the automated analysis, interpretation, and classification of somatic variants in oncology. Through an integrated environment, the system evaluates clinical evidence in real time, automates classification in accordance with AMP/ASCO/CAP guidelines, and provides access to currently active clinical trials. Detailed description Operating principle End-to-end cloud-based solution for the clinical interpretation…
Qiagen
Next Generation Sequencing (NGS)

SeqOne Genomics – Somatic

SeqOne is a bioinformatics platform for NGS data analysis in precision oncology, designed to detect, prioritise and interpret somatic variants and generate actionable clinical reports from raw sequencing data. It helps laboratories and healthcare professionals accelerate the interpretation of NGS data through an end-to-end workflow. Detailed description Operating principle SeqOne Genomics is a genomic data…
SeqOne
Next Generation Sequencing (NGS)

MSK-ACCESS® powered with SOPHiA DDM™

In-house liquid biopsy solution based on hybrid-capture next-generation sequencing (NGS) technology for the ultrasensitive detection of somatic alterations in circulating cell-free DNA from plasma. Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it implements a robust matched tumor-normal sequencing approach (plasma cfDNA + white blood cell DNA) to filter germline variants and mutations…
SOPHIA Genetics
Next Generation Sequencing (NGS)

MSK-IMPACT® / MSK-IMPACT® FLEX

Decentralised, in-house comprehensive genomic profiling (CGP) solution for solid tumours, based on hybrid capture next-generation sequencing (NGS). Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it features a robust matched tumour-normal sequencing approach for filtering germline variants and clonal haematopoiesis. Detailed description Operating principle The decentralised MSK-IMPACT® powered with SOPHiA DDM™ solution enables…
SOPHIA Genetics
Next Generation Sequencing (NGS)